Gilenbay's integrin αvβ3-targeted therapeutic radiopharmaceutical, ¹⁷⁷Lu-AB-3PRGD2, demonstrated promising clinical results in a Phase I/II investigator-initiated trial presented at the ASCO 2026 Rapid Oral Abstract Session. The study enrolled 22 heavily pretreated patients with advanced metastatic solid tumors, showing a median PFS of 6.4 months and median OS of 18.5 months in those receiving ≥2 treatment cycles, with 50% achieving stable disease and 20% partial response. The agent exhibited a manageable safety profile, with a 20% rate of Grade 3+ adverse events. As a Class 1 innovative drug in China, ¹⁷⁷Lu-AB-3PRGD2 leverages a theranostic platform anchored by its companion diagnostic, ⁹⁹ᵐTc-3PRGD2—approved in April 2026 as the world’s first αvβ3-targeted imaging agent—marking a significant advance in precision oncology for end-stage cancer patients.

Unlike conventional cell therapy technology pathways, iRegene deeply integrates AI-driven omics analysis with precise functional control of cells through chemical induction, forming a standardized, replicable, and industrially scalable research and development methodology that addresses common industry challenges at the foundational level.

Guangdong True Health Medical Technology Development Co., Ltd. (TrueHealth), China's top percutaneous and ablation surgical robot company since 2022, has filed a confidential prospectus for a Chapter 18A listing on the HKEX Main Board. Founded in 2018 and headquartered in Zhuhai, TrueHealth specializes in precision needle-guided robotics for lung and abdominal procedures and microwave ablation systems for liver tumors. Its flagship products—TH-S series (percutaneous robots) and TH-X MW/HMW (microwave ablation robots)—have received NMPA approval, with additional pipeline products in development. Despite minimal FY2024 revenue of CNY 1.79 million and a net loss of CNY 92.16 million, the company maintains a strong IP portfolio with 203 patents and targets a CNY 2.3 billion addressable market in China by 2032. Proceeds from the IPO will support commercialization, R&D, and working capital.

Computed tomography (CT) has long remained one of the most technically sophisticated tracks in the medical imaging field. A complete CT system involves multiple core industrial links, including X-ray tubes, high-voltage generators, detectors, image reconstruction algorithms, motion control systems and post-processing software. Among these core components, detectors and X-ray tubes have historically been recognized as key technical bottlenecks restricting industrial development, while image reconstruction algorithms and low-dose imaging capabilities directly determine the clinical performance of CT devices.

Taking type 2 diabetes mellitus as an example, research data published in the Chinese Circulation Journal indicates that the prevalence of diabetes in China reached 15.88% in 2023, with the number of affected individuals surging to 230 million – a 163% increase compared to 2005 (88.48 million). Researchers predict that without timely intervention, the healthcare costs associated with diabetes and its complications (such as retinopathy, nephropathy, and cardiovascular disease) will exceed USD 460 billion by 2030.

This study aims to evaluate the safety, tolerability, and preliminary efficacy of XTR022 in previously treated, PSMA-positive mCRPC subjects. Among the 13 subjects with at least one post-treatment PSA assessment, 10 achieved a PSA50 response (76.9%, with one case pending confirmation), and 5 achieved a PSA90 response (38.5%). Among 9 subjects with RECIST-measurable lesions, the objective response rate (ORR) was 33.3% (3 partial responses), and the disease control rate (DCR) was 88.9%.

This study holds three core industrial values: first, it validates the feasibility and superior efficacy of "ADC plus IO" in first-line lung cancer treatment at the highest level of evidence-based medicine, expanding the clinical application boundaries of combination therapy; second, it confirms that the TROP2 target is not only applicable to later-line salvage therapy but can also meet the stringent efficacy requirements for first-line treatment; third, it marks the official transition of Chinese-produced antibody-drug conjugates from fast-follow innovation to a new stage of participating in defining global oncology treatment standards.

Following this financing round, HemaCell plans to initiate a pre-initial public offering (pre-IPO) round within the year to fund the establishment of manufacturing bases and expand production capacity. The company aspires to bring Chinese-originated innovation to the global platelet therapeutics field and usher in the second revolution in transfusion medicine.

June 2, 2026—MIL Medical Technology (Shenzhen) Co., Ltd.(MIL MED TECH), China’s leading multi-scenario laser medical technology platform developer, has closed its hundred-million-yuan Series B fundraising round. The round is led by Guangdong-Hong Kong-Macao Greater Bay Area Guidance Fund, managed by Shenzhen Capital Group Co., Ltd.(SCGC), with co-investment from Nanshan SEI Investment and Shunbo Fund. Existing backer Shenzhen HTI Group Co., Ltd.(HTI) made follow-on incremental investment, while WinX Capital continued to serve as the company’s exclusive financial adviser. Proceeds from the Series B will be primarily allocated to clinical registration and commercial launch of multi-department laser medical devices, iterative R&D for core laser technologies, and the construction of the firm’s global sales network.

Eclipse Bioinnovations, Inc. (Eclipsebio) has expanded its eCOMPASS™ platform with the launch of eSENSE Break™, a next-generation sequencing technology that maps RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution. Designed to address a critical challenge in RNA therapeutic development, eSENSE Break™ provides precise positional data on where and why RNA molecules break, enabling smarter molecular design and manufacturing optimization for linear mRNA, self-amplifying RNA, and circular RNA therapeutics. Integrated with Eclipsebio’s eMERGE™ analytics suite and eSHAPE™ structure profiling, the technology empowers developers to correlate fragmentation patterns with RNA secondary structure, advancing proactive stability engineering across the RNA therapeutic pipeline.

A major strategy in the promotion of dotinurad is trading price for volume to rapidly capture market share. Leveraging Eisai's robust and well-established distribution network, dotinurad was prescribed simultaneously in Beijing and Shanghai on the first day following its approval, with market availability across multiple regions in China within 72 hours, ensuring a highly efficient commercial launch. Regarding pricing strategy, Eisai swiftly advanced dotinurad's inclusion in the national medical insurance program. Just one year post-approval, the drug was incorporated into medical insurance coverage, substantially lowering patients' out-of-pocket burden. Since the implementation of the 2026 medical insurance reimbursement policy, patient reports indicate that the out-of-pocket cost for dotinurad (20 mg × 14 tablets/box) stands at merely RMB 23.36 after reimbursement.

This study aims to evaluate the safety, tolerability, and preliminary efficacy of XTR022 in previously treated, PSMA-positive mCRPC subjects. Among the 13 subjects with at least one post-treatment PSA assessment, 10 achieved a PSA50 response (76.9%, with one case pending confirmation), and 5 achieved a PSA90 response (38.5%). Among 9 subjects with RECIST-measurable lesions, the objective response rate (ORR) was 33.3% (3 partial responses), and the disease control rate (DCR) was 88.9%.

In contrast, diagnostic and treatment services for conditions such as cataracts and fundus diseases have a public-service character and involve the management of complex cases, resulting in a relatively lower gross profit margin. In 2025, the gross profit margin for cataract procedures was 33.5%, while that for posterior segment procedures stood at only 27.6% . Although this type of business offers limited profit margins, it enhances Aier Eye Hospital's comprehensive ophthalmic diagnostic and treatment capabilities, boosts brand reputation and industry influence, and establishes a complementary model where "high-margin consumer services generate profits, while inclusive clinical services build brand reputation."

If the STAR Market is Sinocelltech's domestic foundation, then this Hong Kong initial public offering is its global launchpad. With the STAR Market as the base and the Hong Kong stock market as the international window, Sinocelltech is building an A+H dual capital platform. Leveraging the international rules of the Hong Kong stock market, coverage by global institutional investors, and the advantages of cross-border financing, the company aims to broaden its financing channels and enhance its international brand influence. It is clear that Sinocelltech is fully accelerating overseas clinical trials, overseas listings, and global business collaborations.

EBV is the first human tumor-associated virus. Ninety-five percent of the global adult population is infected and carries the virus for life. Long-term infection can lead to various tumors, including nasopharyngeal carcinoma, lymphoma, and EBV-associated gastric cancer. The lead pipeline candidate of CR Therapeutics' TCR-T in vivo platform, CR101, has demonstrated excellent efficacy in clinical studies of patients with advanced EBV-associated tumors who have failed multiple lines of therapy, have multiple metastases throughout the body, and are resistant to PD-1 antibodies.

On May 27, 2026, WIRAXON announced the completion of its series angel financing totaling over 300 million yuan. The round was led by Cathay Capital, with SSCILF and Sherpa as co-lead investors, and HENGXU CAPITAL as a follower. Existing shareholder Innovation&Entrepreneurship also increased its stake. The raised funds will be mainly used for national multi-center registered clinical trials of the implanted spinal-cerebral interface technology, the construction of its headquarters in Waigaoqiao, Pudong, and global strategic layout, to accelerate the application of the technology and benefit some 20 million patients with spinal cord injuries across the globe.

In 2025, China’s domestic laparoscopic surgical robots saw explosive sales growth, with MedBot and Edge Medical reporting year-on-year revenue growth of 114% and 185% amid rapid large-scale adoption and deployment. While global leader Intuitive Surgicalgenerates steady recurring revenue through its integrated equipment, consumables, and services model—with its da Vinci system completing over 400 annual surgeries per unit in China—domestic devices are seeing fast-rising utilization rates. MicroPort’s Toumai system registers 230 annual surgeries per unit with over 140 commercial installations. Despite strong market potential, domestic players must further improve these utilization rates to drive sustainable long-term profitability.

According to data cited by both parties, China's advanced wound care market is growing at an annual rate of 6%-8%, far surpassing the 2%-3% growth in Europe and the United States. Within this, the market size for advanced wound dressings is approximately 3 billion RMB. Behind this high growth are multiple contributing factors: the world's largest population of diabetes patients has driven up the incidence of diabetic foot ulcers; an aging population has exacerbated pressure ulcer issues; and demand from surgeries and cosmetic procedures has fueled a surge in scar management.

2026 Future Healthcare and Medicine Conference · Panlin Capital Post-investment Empowerment Seminar centers on reassessing high-quality assets within China’s innovative medical sector. At the 2026 AACR Annual Meeting, 104 Chinese pharmaceutical enterprises showcased over 250 research achievements, breaking the dominance of multinational industry giants. In 2025, China granted approval to 76 innovative drugs and 76 innovative medical devices. As of 2026, the total value of BD transactions involving domestic innovative drugs has surpassed $49 billion. China’s medical innovation industry is evolving from a fast follower into a systematic innovator. Multinational corporations have fundamentally adjusted their evaluation criteria for Chinese medical innovative assets and shifted focus to strategic industrial layout. Li Yuhui, Founding Managing Partner of Panlin Capital, stated that revaluing premium innovative medical assets in China has become a core industry topic.

DVT most commonly occurs in the lower extremities, and its major adverse consequences are pulmonary thromboembolism (PE) and post-thrombotic syndrome (PTS). Acute PE has a mortality rate as high as 20%–30%, representing an extremely high risk of fatality. If acute DVT is not diagnosed and treated in a timely manner, it can progress to chronic DVT, with 30%–50% of patients developing PTS within two years。

On May 27, 2026, GlaxoSmithKline (GSK) re-submitted its marketing application for bepirovirsen injection—a first-in-class antisense oligonucleotide (ASO) therapy—for the finite-duration treatment of chronic hepatitis B in China. This follows the rejection of its initial priority-reviewed application on May 25, 2026. The new filing (acceptance number JXHS2600056) targets adult patients on nucleos(t)ide analog therapy with HBsAg ≤3,000 IU/mL and no cirrhosis. Bepirovirsen, licensed from Ionis Pharmaceuticals in a $262M deal, demonstrated statistically significant functional cure rates in Phase III B-Well 1/2 trials involving over 1,800 patients across 29 countries. The drug employs a triple mechanism: degrading HBV RNA, suppressing viral replication and HBsAg, and activating immune response. If approved, it could become the first finite six-month treatment for chronic HBV, transforming the current lifelong therapy paradigm.

On May 19, 2026, five major therapeutic breakthroughs were reported: (1) Fractyl Health’s RJVA-001, the world’s first AAV gene therapy for Type 2 Diabetes, entered Phase I/II trials, enabling meal-responsive GLP-1 secretion via pancreatic delivery; (2) Hejia Biotech’s Lp(a)-targeting siRNA drug Kylo-11 completed China Phase II enrollment, showing 96.7% Lp(a) reduction at 24 weeks with potential once-yearly dosing; (3) Sun Yat-sen University’s Fifth Affiliated Hospital launched a new Cell Therapy Center in Zhuhai focusing on cell therapy, gene editing, and brain-computer interfaces; (4) CHIATAI TIANQING partnered with GSK to commercialize Bepirovirsen in China, a 6-month finite-course therapy for functional cure of chronic hepatitis B that met its Phase III primary endpoint; (5) BeOne Medicines’ BCL2 inhibitor Sonrotoclax (Beqalzi) received FDA accelerated approval for relapsed/refractory mantle cell lymphoma, achieving 52% ORR and 16% CR in heavily pretreated patients.

In the first quarter of 2026, innovative drug revenue accounted for 61.69% of Hengrui Pharma's total revenue, a year-on-year increase of 25.75%. Zanubrutinib of BeOne Medicines recorded quarterly sales close to 8 billion yuan. RemeGen registered a net profit attributable to shareholders of 328 million yuan, yet its non-deducted net profit remained negative. Chinese innovative drugs continue to gain greater influence across the global market. In 2025, China held 30% of the world’s investigational new drug pipelines, and the total value of overseas out-licensing transactions surpassed $130 billion. Driven by rising sales of its products covering oncology, metabolic and cardiovascular diseases, immunology and respiratory diseases, as well as growing BD income, Hengrui Pharma achieved steady growth in sales revenue from innovative drugs.

Affected by the licensing news, the share price of Hengrui Pharma surged in the afternoon. Its A-share once rose over 9%, with its market value breaking through the 380 billion RMB mark; its H-share once surged over 16%.

On May 11, 2025, Sino Biopharm announced that its subsidiary CHIATAI TIANQING has entered an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the commercialization of bepirovirsen, a first-in-class antisense oligonucleotide (ASO) therapy with triple mechanism of action, in mainland China. CHIATAI TIANQING will manage import, distribution, hospital access, and all promotional activities, recognizing 100% of sales revenue, while GSK remains the Marketing Authorization Holder responsible for regulatory, quality, and global medical strategy. The initial term is 5.5 years, extendable by mutual agreement. Bepirovirsen, submitted for Chinese marketing approval in March 2026 and granted priority review, demonstrated significant functional cure rates in Phase III B-Well trials and could become the first finite-duration therapy to achieve functional cure for chronic hepatitis B—a disease affecting 75 million people in China and causing over 450,000 annual deaths.

In October 2023, Alebund acquired the exclusive commercial rights in China for Roche's long-acting erythropoietin MIRCERA® (AP601). This global first-in-class long-acting erythropoietin (EPO), administered once monthly, is indicated for the treatment of CKD-related anemia. After being included in the National Reimbursement Drug List (NRDL) in 2024, it experienced rapid uptake, contributing RMB 30.556 million in revenue in 2025, accounting for 100% of total revenue.

For pharmaceutical companies, the significance of the CTP is even more direct: securing a spot provides the most authoritative endorsement for a pipeline asset, after which subsequent clinical advancement, out-licensing deals, and commercial rollout become much easier, sometimes even triggering a surge in stock price. As a result, many companies make it their primary goal to get their assets into the CTP. Historically, CTP slots have been locked down by MNCs.

As an investigational human monoclonal antibody targeting CD38, felzartamab possesses significant clinical potential due to its unique mechanism of action. It selectively depletes CD38-positive plasma cells, blocking the generation of pathogenic antibodies at the source.

However, these synergistic integration efforts have not reached the ideal state. Trividia and PTS have often experienced performance losses and goodwill impairment, affecting Sinocare's profits. For example, in 2019, the business operations of PTS were impacted, resulting in goodwill impairment of 25 to 50 million RMB; Trividia's operating loss impacted Sinocare's investment income by approximately -60 to -75 million RMB. In 2020, both PTS and Trividia were in a state of operating loss. In 2021, Trividia continued to incur losses; in 2023, Trividia faced operating losses and goodwill impairment.

Multinational pharmaceutical companies are now capturing high ground in the radiopharmaceutical space through a dual strategy of deep collaboration plus capacity pre-positioning — securing both cutting-edge technologies and project pipelines while also establishing localized production of scarce radionuclides ahead of time. The global radiopharmaceutical competition has formally entered a stage of value-chain positioning battles.